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Objective. Subclinical gut inflammation is com-
mon in spondylarthritis, but the immunologic abnor-
malities underlying this process are undefined. Pertur-
bation of the interleukin-23 (IL-23)/Th17 axis has
emerged as a fundamental trigger of chronic inflamma-
tion. This study was undertaken to investigate the expres-
sion and tissue distribution of IL-23/Th17–related mol-
ecules in Crohn’s disease (CD) and in subclinical gut
inflammation in ankylosing spondylitis (AS).
Methods. Quantitative gene expression analysis
of Th1/Th2 and IL-23/Th17 responses was performed in
intestinal biopsy samples obtained from 12 patients with
CD, 15 patients with AS, and 13 controls. IL-23 tissue
distribution and identification of IL-23–producing cells
were evaluated by immunohistochemistry.
Results. We demonstrated a strong and signifi-
cant up-regulation of IL-23p19 transcripts in the termi-
nal ileum in patients with AS and patients with CD.
IL-23 was abundantly produced by infiltrating monocyte-
like cells in inflamed mucosa from AS and CD patients.
Notably, we also identified Paneth cells as a major
source of IL-23 in patients with AS, patients with CD,
and normal controls. Unlike CD, in AS patients, IL-23
was not associated with up-regulation of IL-17 and the
IL-17–inducing cytokines IL-6 and IL-1. Finally, while
the Th1-related cytokines interferon-, IL-12p35, and
IL-27p28 were overexpressed only in CD patients, IL-4,
IL-5, and STAT-6 were also significantly increased in
AS patients.
Conclusion. Our findings indicate that overex-
pression of IL-23, but not IL-17, is a pivotal feature of
subclinical gut inflammation in AS. Identification of
resident Paneth cells as a pivotal source of IL-23 in
physiologic and pathologic conditions strongly suggests
that IL-23 is a master regulator of gut mucosal immu-
nity, providing a pathophysiologic significance to the
reported association between IL-23 receptor polymor-
phisms and intestinal inflammation.
Asymptomatic intestinal inflammation, usually
involving the terminal ileum, has been demonstrated in
a significant number of patients with spondylarthritis
(SpA) (1). Historically, 2 types of inflammation have
been observed in patients with SpA: acute inflammation
as seen in infectious colitis and chronic inflammation
resembling Crohn’s disease (CD). Long-term evolution
to overt CD has been described in 7% of patients with
initial chronic gut inflammation (2).
Several immunologic similarities between gut in-
flammation in SpA and CD have been described, such as
increased expression of the E-cadherin–catenin com-
plex, up-regulation of E7 integrin on intraepithelial T
cells, and increased numbers of macrophages expressing
the scavenger receptor CD163, supporting the concept
that this subgroup of SpA patients may be considered a
model for early immune alterations related to CD (3).
T lymphocytes play an important role in the
regulation of gut immune responses. In vivo and in vitro
studies have demonstrated that dysregulated effector T
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cell responses are involved in the pathogenesis of intes-
tinal inflammation (4). After antigenic stimulation, naive
CD4 T cells differentiate into various subsets that are
characterized by the production of distinct cytokines
with distinct effector functions. This process is governed
by selective cytokines and intracellular pathways, such as
STAT and suppressor of cytokine signaling (SOCS).
Historically, effector T cells have been catego-
rized into 2 main subsets: Th1 cells, which produce large
quantities of interferon- (IFN), and Th2 cells, which
produce interleukin-4 (IL-4), IL-5, and IL-13. Th1 cells
are proinflammatory cells linked to the induction and
progression of Th1-related disorders such as CD (5,6).
Recently, a novel T cell subset characterized by
IL-17 production (Th17) and capable of directly induc-
ing tissue inflammation and autoimmunity has been
shown to be involved in the pathogenesis of several
autoimmune diseases (7). Although it is a subject of
controversy, recent evidence indicates that Th17 cells in
humans are differentiated from naive T cells by the
combination of IL-1, IL-6, and IL-23. Once differenti-
ated, IL-23 triggers the proliferation of Th17 cells from
activated memory T cells. Th17 cells produce IL-17A
and IL-17F and, to a lesser extent, tumor necrosis factor
(TNF) and IL-6 (7,8). Although the primary focus on
IL-23 function has been the Th17 pathway and thus
adaptive immune induction and function, a recent study
(9) identified an important role for IL-23 in directly
activating the innate intestinal immune system, suggest-
ing a pivotal role of IL-23 in regulating local immune
responses in the gut.
The limited data available on cytokine produc-
tion in the gut of SpA patients indicate a small but
significant impairment of Th1 cytokines in lymphocytes
isolated from the colon of SpA patients (10). Activation
of the IL-17/IL-23 and STAT pathways and the expres-
sion of negative regulator protein SOCS-3 in the intes-
tine of SpA patients have not been evaluated as yet. The
aim of this study was to evaluate the IL-23/Th17 axis, in
parallel with Th1 and Th2 responses, in subclinical gut
inflammation in patients with ankylosing spondylitis
(AS). In addition, we aimed to identify the main cellular
source(s) of IL-23 in normal intestinal mucosa and in the
inflamed intestinal mucosa of patients with AS and
patients with CD.
This is the first study to show that IL-23 is
markedly up-regulated at the messenger RNA (mRNA)
and protein levels in the terminal ileum in AS patients at
levels similar to those found in CD patients. Notably, we
demonstrate that, together with monocyte-like cells in
the inflammatory infiltrates in AS and CD mucosa,
resident Paneth cells are a major source of IL-23 in the
intestinal mucosa under pathologic as well as physiologic
conditions. This suggests a novel and critical role of
Paneth cells in regulating mucosal immunity in the
terminal ileum and in promoting local inflammation via
dysregulated IL-23 expression.
PATIENTS AND METHODS
Patients and controls. Multiple biopsy specimens were
obtained after informed consent from 15 patients with AS, 12
patients with CD, and 13 controls who underwent ileocolonos-
copy for routine clinical evaluation. Independently of the
presence of gastrointestinal symptoms, patients with AS were
systematically referred by the rheumatologist for an ileo-
colonoscopy with biopsies.
Table 1 shows the baseline characteristics of the pa-
tients and controls. The AS group consisted of 9 men and 6
women with a median age of 41 years (range 38–65 years) who
were diagnosed as having AS according to the modified New
York criteria (11). Disease activity was evaluated using the
Bath AS Disease Activity Index (BASDAI) (12), with a
BASDAI score of 4 indicating active disease. All patients
were HLA–B27 positive. At the time mucosal biopsy speci-
mens were obtained, the mean SD BASDAI score was 6.7
3.4, and none of the patients had ever received cytotoxic
treatment. The CD group consisted of 8 men and 4 women
with a median age of 50 years (range 48–60 years). The
diagnosis of CD was made according to clinical parameters and
findings of radiographic, endoscopic, and histopathologic anal-
yses. Disease activity was evaluated using the CD Activity
Index (13), with a score 150 indicating active disease, and
endoscopic and histopathologic data. At the time of sample
collection, the mean  SD CD Activity Index score was 253 
51.5, and none of the patients had received steroids and/or
cytotoxic drugs, immunosuppressive agents, or antibiotics. The
control group consisted of 8 men and 5 women with a median
age of 45 years (range 41–58 years) who were undergoing
ileocolonoscopy for diagnostic purposes and in whom there
was no evidence of underlying disease.
Two adjacent mucosal biopsy samples from each intes-
tinal segment (rectum, descending colon, transverse colon,
ascending colon, cecum, and terminal ileum) were obtained
from each subject. One sample was used for immunohistology
and the other for transcript analysis. In addition, small intes-
tine biopsy specimens from 4 patients with ulcerative colitis
(UC) and 2 with Behc¸et’s disease (BD) were analyzed. The
study was approved by the ethics committee and the institu-
tional review board of the University of Palermo.
Quantitative TaqMan reverse transcriptase–polymerase
chain reaction (RT-PCR) for Th1, Th2, and Th17 cytokines,
STAT molecules, and SOCS-3. Total RNA was extracted using
the Qiagen RNeasy Mini kit (Qiagen, Chatsworth, CA), with
on-column DNase I digestion. A total of 1 g of RNA was
reverse-transcribed to complementary DNA (cDNA) using a
ThermoScript First-Strand cDNA Synthesis kit (Invitrogen,
Carlsbad, CA). For quantitative TaqMan real-time PCR, sets
of primers and probes were obtained from Applied Biosystems
(Foster City, CA) (see Supplementary Table 1, available
online at http://www3.interscience.wiley.com/journal/
76509746/home). Samples were run in triplicate at 20 ng of
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cDNA per well and detected using an ABI Prism 7900HT
instrument. Results were analyzed using ABI Prism 7900HT
Sequence Detection System version 2.1 software. Relative
quantification was assessed using the Ct method.
Histomorphologic grading. Tissue samples were fixed
in 10% buffered formalin, dehydrated, and embedded in
paraffin. Sections (3 m thick) were deparaffinized, rehy-
drated, and stained with hematoxylin and eosin. Specimens
from patients with AS were divided into 3 subgroups as
previously described (14): those with normal gut histology,
those with acute inflammation, and those with chronic inflam-
mation. Briefly, acute inflammation was defined by the pres-
ervation of normal architecture, with the presence of neutro-
phils and/or eosinophils in the crypt and villus epithelium.
Chronic inflammation was defined by alterations of the muco-
sal architecture, with crypt distortion and atrophy in the colon,
and villous blunting and fusion in the ileal mucosa, with an
active granulocytic infiltrate in the epithelium accompanied by
an increased mononuclear cell infiltrate and formation of basal
lymphoid aggregates in the lamina propria.
Immunohistochemical localization and identification
of IL-23– and IL-17–producing cells in the intestinal mucosa.
Immunohistochemistry for IL-23 and IL-17 was performed on
3-m–thick paraffin-embedded sections. Following rehydra-
tion, antigen was unmasked for 45 minutes at 95°C using Dako
Target retrieval solution (pH 6; Dako, Carpinteria, CA).
Endogenous peroxidase was blocked for 10 minutes with Dako
peroxidase blocking reagent, and nonspecific binding was
blocked for 20 minutes with Dako protein block. The primary
antibodies mouse monoclonal anti-human IL-23p19 (IgG1,
clone HLT2736; 1:50 dilution) (BioLegend, San Diego, CA) or
rabbit anti-human IL-17 (1:100 dilution) (Santa Cruz Biotech-
nology, Santa Cruz, CA) were added and incubated for 1 hour
at room temperature. An isotype-matched irrelevant antibody
was used as a negative control. Following 3 washes with Tris
buffered saline, slides were incubated for 30 minutes with
peroxidase-conjugated Dako EnVision polymer. After 3 fur-
ther washings, peroxidase activity was visualized using di-
aminobenzidine chromogen (Dako), and slides were lightly
counterstained with hematoxylin before dehydration and
mounting in DePex (VWR International, Oslo, Norway). In
order to identify Paneth cells (15) as a possible source of IL-23
in the intestinal crypts, double immunohistochemical staining
for defensin 5 and IL-23 was performed using a Dako EnVi-
sion double staining kit. For defensin 5 detection, a mouse
monoclonal antibody to human -defensin NP5 (Abcam, Cam-
bridge, UK) was incubated for 1 hour at room temperature at
a 1:50 dilution, and staining was developed as described above.
The number of IL-23– and IL-17–expressing cells was
determined by counting IL-23– or IL-17–immunoreactive cells
on photomicrographs obtained from 3 random high-power
microscopic fields (400 magnification) under a Leica
DM2000 optical microscope, using a Leica DFC320 digital
camera (Leica, Rijswijk, The Netherlands). Scoring was per-
formed by 2 experienced pathologists (CT and VF) who were
blinded with regard to subject group. Results are reported as
the mean  SD.
Statistical analysis. Statistical analysis of quantitative
variables was performed using the Kruskal-Wallis nonpara-
metric test, with Dunn’s post test when analyzing more than 2
groups and the Mann-Whitney U test when analyzing 2 groups.
P values less than 0.05 were considered significant.
RESULTS
Prevalence and histomorphologic evaluation of
subclinical intestinal inflammation in AS patients. Of
the 15 patients with active AS who underwent colonos-
copy (mean BASDAI score 6.7), evidence of subclinical
intestinal inflammation was observed in 11 (73%). In all
cases, microscopic inflammatory lesions were observed
only in the distal ileum and/or cecum, with other intes-
Table 1. Baseline characteristics of the patients and controls*
CD patients
(n  12)
AS patients
(n  15)
Controls
(n  13)
Age, mean  SD years 50 10 41  14 45  13
Sex, no. (%) male 8 (66) 9 (60) 8 (62)
Disease duration, mean  SD months 5  1.5 6 3.8 NA
Intestinal area involved, no. (%) of patients
Ileum 12 (100) NA NA
Ileum and colon 5 (42) NA NA
CRP, mean  SD mg/liter 22 8 10  6† NA
Concomitant medical treatment, no. (%)
Corticosteroids 0 (0) 0 (0) NA
NSAIDs 0 (0) 7 (47) NA
Immunosuppressants 0 (0) 0 (0) NA
5-aminosalicylates 0 (0) 0 (0) NA
CD Activity Index score, mean SD‡ 253  51.5 NA NA
BASDAI score, mean  SD§ NA 6.7 3.4 NA
* AS  ankylosing spondylitis; NA  not applicable; CRP  C-reactive protein; NSAIDs  nonsteroidal
antiinflammatory drugs.
† P  0.0005 versus patients with Crohn’s disease (CD).
‡ Scores for the CD Activity Index range from 0 to 600, with higher scores indicating more severe disease.
§ Scores for the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) range from 0 to 10, with
higher scores indicating more severe disease.
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Figure 1. Interleukin-23 (IL-23)/Th17–related gene expression in mucosal biopsy specimens from patients with ankylosing spondylitis (AS), patients
with Crohn’s disease (CD), and normal controls. Relative mRNA quantification of IL-23/Th17–related cytokines and transcription factors IL-23p19
(A), STAT-3 (B), IL-17A (C), IL-6 (D), IL-1 (E), transforming growth factor  (TGF) (F), and suppressor of cytokine signaling 3 (SOCS-3) (G)
was assessed by TaqMan real-time polymerase chain reaction in ileal/cecal biopsy specimens obtained from 12 patients with CD, 15 patients with
AS, and 13 normal controls. Patients with AS were further divided into 2 groups: those with normal histologic findings or acute inflammation and
those with chronic inflammation. Bars show the mean and SEM. NS  not significant.
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tinal segments unaffected. On the basis of gut histology,
as defined above and as previously described (14),
patients with AS were divided into 2 main groups: those
with normal histologic features or minor inflammation
(acute lesions; 8 patients) and those with chronic inflam-
mation (7 patients).
IL-23 mRNA is strongly up-regulated in the
intestinal mucosa of AS patients to levels similar to
those found in CD patients, but is not associated with a
well-defined Th17 response. We investigated whether
subclinical gut inflammation in AS patients was charac-
terized by up-regulation of cytokines and transcription
factors involved in the IL-23/Th17 axis. Although it is a
subject of controversy, the differentiation and expansion
of human Th17 have recently been shown to be regu-
lated by IL-23, IL-1, and IL-6 (8,16). While transform-
ing growth factor  alone stimulates the polarization of
human CD4 T cells into regulatory T cells by increas-
ing FoxP3 (17), and suppressing the differentiation of
Th1, Th2, and Th17 lymphocytes, the concomitant stim-
ulation of IL-1 and IL-6 induces the generation of the
proinflammatory Th17 phenotype (8). Once differenti-
ated, Th17 cells need stimulation by IL-23 to expand and
maintain the Th17 phenotype. The IL-23 signal seems to
be mediated by STAT-3 and inhibited by SOCS-3
(18,19).
We first evaluated the mRNA expression levels
of cytokines involved in Th17 immune responses in
different intestinal segments in patients with AS, pa-
tients with CD, and histologically normal controls. The
analysis among the different patient groups was per-
formed by comparing the expression levels of each gene
within the same intestinal segment. Differential expres-
sion of inflammatory cytokines in AS patients compared
with normal controls was observed in the cecum and
distal ileum but not in the rectum, descending colon,
transverse colon, or ascending colon. Thus, analysis was
performed comparing results obtained from cecal/ileal
biopsy specimens only. In addition, a comparative ana-
lysis within AS patients was performed by subgrouping
patients with AS with chronic inflammation versus those
with acute inflammation or normal histologic findings.
As shown in Figure 1A, a marked and significant
increase in ileal expression of IL-23p19 transcripts was
observed in AS patients (4-fold compared with control
intestinal biopsy specimens), to levels similar to those
seen in CD patients. The increase in IL-23p19 mRNA
expression was particularly evident in mucosal biopsy
specimens obtained from AS patients with chronic as
compared with acute inflammation. Of relevance, an
abundant (compared with most cytokines tested) basal
expression of IL-23p19 mRNA was observed in the
ileum of normal controls, suggesting a constitutive ex-
pression of IL-23 in this segment. Notably, up-regulation
of IL-23p19 was not observed in the ileum of 4 patients
with UC and 2 patients with BD (data not shown).
Consistent with IL-23p19 up-regulation, STAT-3,
which mediates IL-23 signaling upon IL-23 receptor
(IL-23R) ligation, was significantly increased in AS
patients, to levels similar to those found in CD patients
(Figure 1B). Despite the strong up-regulation of IL-23
mRNA detected, we observed only a modest and not
statistically significant increase in IL-17A mRNA in the
same segments (Figure 1C). Accordingly, cytokines in-
volved in Th17 differentiation, such as IL-6 and IL-1,
were only modestly increased or not increased in AS
patients (Figures 1D and E). However, trends (although
not statistically significant) toward higher levels of IL-17,
IL-6, and IL-1 mRNA were detected in AS patients
with chronic lesions versus those with acute lesions. In
contrast to patients with AS, patients with CD displayed
a marked increase in IL-17A, IL-6, and IL-1 expression
compared with controls (Figures 1C–E), confirming the
coexistence of IL-23 up-regulation and Th17 responses
in intestinal inflammation in CD. SOCS-3 was overex-
pressed in CD patients (10-fold increase compared
with control levels), but not in AS patients (Figure 1G).
Expression of Th1 and Th2 cytokines and related
STAT genes in the intestinal mucosa of AS patients. We
next evaluated the mRNA expression levels of multiple
cytokines involved in Th1 and Th2 immune responses.
As shown in Figure 2, intestinal biopsy specimens from
AS patients, analyzed independently of the degree of
intestinal inflammation, did not show any significant
increase in the expression levels of IFN, IL-12p35,
IL-27p28, or the Th1-related signaling molecule STAT-1
(Figures 2A–D) as compared with controls. Conversely,
as expected, evident overexpression (10-fold increase)
of IFN was detected in patients with CD. Consistent
with IFN up-regulation, concomitant overexpression of
IL-12p35 (2-fold), IL-27p28 (5-fold), and STAT-1 (2-
fold) was observed in samples from patients with CD.
Interestingly, a trend toward an increase in Th1-related
genes was observed in patients with AS displaying
chronic inflammation as compared with those with nor-
mal histologic findings or acute inflammation, although
the differences were not significant.
In patients with CD, a significant increase in ileal
expression of TNF transcripts was also observed as
compared with controls (4-fold), while no significant
up-regulation of TNF was detectable in AS (Figure
2G). When we analyzed AS patients with chronic inflam-
matory lesions alone, a more evident, although not
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statistically significant, increase in TNF mRNA levels
(2-fold) was detected.
We analyzed the Th2 profile of intestinal ileal/
cecal biopsy specimens from patients with AS. Interest-
ingly, increases in IL-4 and IL-5 mRNA were observed
in patients with AS as well as in patients with CD. In AS
Figure 2. Characterization of Th1- and Th2-related gene expression profiles in mucosal biopsy specimens
from patients with AS, patients with CD, and normal controls. Relative mRNA quantification of Th1- and
Th2-related cytokines and transcription factors interferon- (IFN) (A), IL-12p35 (B), IL-27p28 (C),
STAT-1 (D), IL-4 (E), STAT-6 (F), tumor necrosis factor  (TNF) (G), and IL-5 (H) was assessed by
TaqMan real-time polymerase chain reaction in ileal/cecal biopsy specimens obtained from 12 patients
with CD, 15 patients with AS, and 13 normal controls. Patients with AS were further divided into 2 groups:
those with normal histologic findings or acute inflammation and those with chronic inflammation. Bars
show the mean and SEM. See Figure 1 for other definitions.
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patients, IL-4 mRNA expression was increased 3.5-
fold and IL-5 mRNA expression was increased 5-fold,
and in CD patients, IL-4 mRNA expression was in-
creased 5.5-fold and IL-5 expression was increased
30-fold, compared with controls (Figures 2E and H).
Similarly, STAT-6, which mediates IL-4 signaling upon
IL-4R ligation, was also increased in AS patients (2-fold
compared with controls), to levels similar to those found
in patients with CD (Figure 2F). Interestingly, both in
AS and CD, patients with high levels of IL-4 mRNA
displayed low IFN expression, suggesting the presence
of different stages of evolution of the inflammatory
lesions (data not shown). In contrast, IL-13 mRNA
expression was detectable in only 2 of 15 patients with
AS and 2 of 12 patients with CD.
Identification of Paneth cells and infiltrating
monocyte-derived cells as the cellular sources of IL-23
in the terminal ileum of patients with AS and patients
with CD. Given the strong up-regulation of IL-23
mRNA in mucosal biopsy specimens from patients with
AS or CD, we next investigated its protein expression
and distribution pattern. Immunohistochemical analysis
of samples from AS patients and CD patients demon-
strated 2 different patterns of IL-23 expression in the
terminal ileum. The first pattern was a unique feature of
CD and AS with chronic inflammatory lesions and was
characterized by a large number of IL-23–producing
cells within the lymphomonocytic inflammatory infil-
trates (Figures 3A–C). IL-23 infiltrating cells were
never observed in normal controls and were only detect-
able in and around inflammatory aggregates in patients
with AS or CD. The morphologic appearance of IL-23
infiltrating cells was mainly characterized by a large
cytoplasm and often dendritic morphology, consistent
with a monocyte-derived cell lineage (i.e., macrophages/
dendritic cells). This expression pattern was similar to
that observed in human lymph nodes (results not
shown).
A second pattern of IL-23 expression was detect-
able in the terminal ileum of CD patients, in AS patients
irrespective of the presence or absence of inflammatory
lesions, and in normal controls. This second pattern was
characterized by abundant expression of IL-23 in the
crypts where IL-23 was produced by epithelial cells
localizing deep within the crypts (Figures 3D–F).
We then compared the number of IL-23 cells in
samples from AS patients, CD patients, and normal
controls. As shown in Figure 3G, terminal ileal biopsy
specimens from AS patients with chronic inflammatory
lesions showed the highest fraction of IL-23–expressing
cells (mean  SD 35.6  7) at levels similar to those in
patients with CD (29.4  6.14) and significantly higher
than in controls (16.8  4.87), confirming the up-
regulation of IL-23p19 mRNA detected by RT-PCR.
Based on morphologic appearance and localiza-
tion within the crypts, IL-23 epithelial cells highly
resembled Paneth cells. In order to confirm this obser-
vation, we performed sequential section analysis and
double immunohistochemistry for IL-23 and defensin 5,
a specific marker of Paneth cells (15). IL-23 and defen-
sin 5 strictly colocalized within the deeper part of the
crypts (Figure 4), allowing the precise identification of
Paneth cells as IL-23–producing cells under pathologic
and physiologic conditions.
Figure 3. IL-23 expression by infiltrating immune cells within inflam-
matory lesions in the terminal ileum of patients with CD or AS. A–F,
Representative photomicrographs showing 3-m–thick paraffin-
embedded sections of distal ileal biopsy specimens obtained from
patients with CD (A, B, and D), patients with AS (C and E), and
normal healthy subjects (NHS) (F), stained for IL-23p19. Abundant
IL-23 expression was observed in a large number of mononuclear cells
infiltrating the intestinal mucosa of samples from patients with CD and
patients with AS (A–C), but not in normal subjects. In both CD and
AS, IL-23 was expressed by immune cells (arrowheads in B and C) with
a large cytoplasm and often dendritic morphology (A) localizing in
proximity to the intestinal lumen (asterisks in B and C). Together with
infiltrating cells, strong expression of IL-23 was invariably observed
within epithelial crypts in close proximity to mononuclear inflamma-
tory infiltrates in both CD patients (D) and AS patients (E). IL-23 was
also observed in the crypts in normal controls (F), consistent with basal
constitutive expression of the protein. (Original magnification 200 in
A, D, E, and F;  400 in B and C.) G, Number of IL-23 cells in the
mucosa. Results are expressed as the number of positive cells per field.
Data are shown as box plots. Each box represents the 25th to 75th
percentiles. Lines inside the boxes represent the median. Lines outside
the boxes represent the 10th and the 90th percentiles. See Figure 1 for
other definitions.
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An increased number of IL-17–producing cells
characterizes the terminal ileum in CD patients but not
AS patients. We used immunohistochemistry to detect
IL-17 cells in the terminal ileum of AS patients and
CD patients. As shown in Figure 5, IL-17–producing
cells were rarely detected in the immune cell infiltrates
in AS but were abundant in CD patients (Figures 5A and
B). Accordingly, quantitative analysis showed that the
number of IL-17 cells in AS patients was not increased
as compared with normal controls, although a trend
toward an increase in IL-17 cells in chronic AS lesions
was apparent (Figure 5C).
DISCUSSION
The presence of a shared pathogenesis between
SpA and CD has been suggested by evidence of similar
arthropathy and intestinal inflammation in patients with
either disease (3). Interestingly, long-term evolution to
overt CD has been described in 7% of patients with SpA
with initial chronic gut inflammation (2). Moreover,
several immunologic similarities between SpA with gut
inflammation and CD have been demonstrated, such as
increased expression of the E-cadherin–catenin com-
plex, up-regulation of E7 integrin on intraepithelial T
cells, and increased numbers of macrophages expressing
the scavenger receptor CD163, supporting the concept
of preclinical CD in patients with SpA with gut inflam-
mation (3). However, the immunologic abnormalities
underlying the inflammatory process in the terminal
ileum of SpA patients are poorly understood.
This is the first study to show that IL-23 expres-
sion is markedly up-regulated at both the mRNA and
protein levels in subclinical intestinal inflammation in
patients with AS, to levels similar to those found in
patients with CD. Interestingly, IL-23 mRNA overex-
pression in AS was associated with up-regulation of
STAT-3, the main transducer of IL-23 signaling upon
IL-23R ligation, indirectly suggesting that the IL-23 axis
is functional in AS and CD patients. Conversely,
SOCS-3, an inhibitor of IL-23 activation, was increased
in CD patients only, suggesting that an imbalance in the
ratio of IL-23 to SOCS-3 may characterize subclinical
gut inflammation in AS.
Based on recent findings, it is becoming increas-
ingly clear that IL-23 exerts an essential pathogenetic
role in promoting autoimmunity and chronic inflamma-
tion in several models of autoimmune diseases, such as
experimental inflammatory arthritis (20) and experi-
mental colitis (21). Our original demonstration of local
IL-23 up-regulation in the terminal ileum of patients
with AS and patients with CD strongly suggests that this
cytokine might also play a pivotal role in promoting
intestinal inflammation and inflammatory bowel disease.
IL-23 is a member of the IL-12 family that drives
Figure 4. Characterization of Paneth cells as the source of IL-23 in intestinal crypts. Representative photomicrographs
showing sequential analysis and double immunohistochemistry of 3-m–thick paraffin-embedded tissue sections of
terminal ileal biopsy specimens obtained from a patient with AS and single stained for anti–IL-23p19 (brown staining)
(A and D) and defensin 5, a specific marker of Paneth cells (red staining) (B), and double stained for IL-23 and defensin
5 (C and E) are shown. Precise colocalization of IL-23 and defensin 5 staining was observed in the distal ileum in AS
patients (as well as in CD patients and controls [results not shown]) at the base of the crypts, consistent with IL-23p19
expression by Paneth cells. Interestingly, while defensin 5 was expressed uniformly in the cytoplasm, IL-23 staining was
mainly polarized toward the apical cytoplasm of Paneth cells. (Original magnification  200 in A–C;  400 in D and E.)
See Figure 1 for definitions.
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a highly pathogenetic T cell population involved in the
initiation of autoimmune diseases. IL-23 is a het-
erodimeric proinflammatory cytokine composed of a
p19 subunit and the p40 subunit; the latter also forms
part of the IL-12 heterodimer with IL-12p35 (22).
Recent evidence suggests that IL-23 acts as a regulator
of the maturation of autoreactive T cells producing
IL-17 (Th17) and promotes chronic inflammation dom-
inated by IL-17, IL-6, IL-8, and TNF, as well as by
neutrophils and macrophages (23–27). Dysregulation of
the IL-23/Th17 axis has been proposed as a major
pathogenetic mechanism leading to the development of
autoimmune diseases, including experimental auto-
immune encephalomyelitis (EAE), inflammatory bowel
disease, rheumatoid arthritis (7), and psoriasis (28).
However, while patients with CD demonstrated a fully
developed Th17 response with high levels of IL-17 and
of the IL-17–inducing cytokines IL-6 and IL-1, this was
not the case in patients with AS, in whom marginal
up-regulation of IL-17 was observed.
Nevertheless, up-regulation of IL-23 is likely to
have profound relevance in regulating intestinal inflam-
mation even independently of IL-17. In this regard,
recent evidence (9) indicates an important role of IL-23
in promoting intestinal inflammation by directly activat-
ing innate immune cells. In an experimental model
characterized by injection of an agonistic anti-CD40
monoclonal antibody into T cell– and B cell–deficient
mice, neutralization of IL-12 resulted in the reversal of
systemicinflammation,withnoeffectonmucosalimmuno-
pathology, while neutralization of IL-23 resulted in
prevention of CD40-induced colitis without affecting
wasting disease or serum cytokines, supporting a specific
role of IL-23 in local mucosal inflammation.
The evidence of IL-23 overexpression in mucosal
biopsy specimens from patients with CD and AS ob-
served in the present study has particular relevance
given the recent demonstration of the association be-
tween the IL-23R gene and inflammatory bowel dis-
eases, with the finding that several independent func-
tional single-nucleotide polymorphisms of the gene and
its neighboring region conferred either strong protection
against or marked susceptibility to CD (29). Recently, it
was also demonstrated that the IL-23R gene could be
involved in genetic predisposition to AS (30,31). How-
ever, the underlying pathogenetic mechanisms related to
the aberrant expression of IL-23 in the gut of SpA
patients need to be investigated. Constitutive p40 pro-
moter activation and IL-23 production by murine ileal
dendritic cells have been demonstrated, suggesting a
predisposition of this segment to developing chronic
inflammatory lesions through IL-23 and providing a
molecular explanation for the preferential clinical man-
ifestation of CD in this segment (32).
The results of this study contribute to the under-
standing of the immunoregulatory properties of IL-23 in
the gut by providing the novel and extremely relevant
observation that, in addition to IL-23 expression by
infiltrating monocyte-like cells in inflamed AS and CD
mucosa, Paneth cells represent a major cellular source of
IL-23 in the terminal ileum in physiologic and pathologic
conditions. Paneth cells are secretory epithelial cells
located at the base of the crypts of Lieberku¨hn in the
small intestine that act as resident host-defense cells by
secreting antimicrobial peptides. Recently, there has
been increasing interest, originally raised by the evi-
dence that these cells produce TNF in the terminal
ileum (33), in the role of Paneth cells in contributing to
intestinal immunoregulation and promoting mucosal
inflammation (for review, see ref. 34).
In this study, we have further expanded the
understanding of the immunoregulatory properties of
Figure 5. An increased number of IL-17–producing cells character-
izes intestinal inflammation in CD but not in AS. A and B, Immuno-
histochemistry for IL-17 (brown staining) in ileal inflammatory lesions
in patients with AS (A) and patients with CD (B). While detection of
IL-17–producing cells (arrows) was relatively rare in AS, abundant
expression of this cytokine was clearly observed in CD. (Original
magnification  200.) C, Number of IL-17 cells in the mucosa in AS
patients with chronic inflammation, AS patients with acute inflamma-
tion, CD patients, and normal healthy subjects (NHS). Results are
expressed as the number of positive cells per field. Data are shown as
box plots. Each box represents the 25th to 75th percentiles. Lines
outside the boxes represent the 10th and the 90th percentiles. Lines
inside the boxes represent the median. See Figure 1 for other
definitions.
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Paneth cells by demonstrating their constitutive expres-
sion of IL-23 under physiologic conditions and their
overexpression of IL-23 in AS and CD. Our findings
suggest that these cells play a fundamental role in
regulating local mucosal immune responses via IL-23.
The identification of basal IL-23 production by Paneth
cells also explains the strong constitutive expression of
mRNA for IL-23p19 in the terminal ileum of normal
individuals. Overall, this suggests that dysregulation of
the IL-23/IL-23R axis (i.e., via IL-23 overexpression
and/or altered IL-23R expression or function) might be
specifically responsible for the increased incidence of
inflammatory lesions observed in this segment. In this
regard, since Paneth cells have been shown to express
NOD-2 (35) and since NOD-2 dysregulation is clearly
implicated in the pathogenesis of CD (36,37), it would
be extremely interesting to investigate whether abnor-
malities in NOD-2 might be responsible for dysregulated
IL-23 expression in Paneth cells.
As briefly discussed above, IL-23 overexpression
in AS was not associated with a fully developed Th17
response, as demonstrated by the relatively low levels of
IL-17 we found. This is possibly related to the low
expression of the IL-17–inducing cytokines IL-6 and
IL-1 in AS compared with their expression in CD. In
this regard, whereas IL-23 triggers the proliferation of
Th17 cells from activated memory T cells, IL-23 alone is
a relatively ineffective inducer of IL-17 and requires the
combination of IL-6 and IL-1 to induce differentiation
of Th17 cells from human naive T cells (8). Conversely,
we confirmed previous reports of elevated IL-17 expres-
sion in the terminal ileum of patients with CD (38).
Evidence of increased Th17 responses in CD is of
particular interest because of the nonredundant role of
Th17 lymphocytes in promoting autoimmunity and
chronic inflammation.
Interestingly, analysis of the kinetics of cytokine
expression in the central nervous system in EAE has
demonstrated that IL-17 peaks before IFN, while IFN
persists in the target tissue even after IL-17 expres-
sion has disappeared. In this regard, while Th17 cells
might be generated more rapidly than Th1 cells during
inflammation and direct the initial acute inflammation,
Th1 cells might function in perpetuating tissue inflam-
mation (39).
Consistent with the results of previous studies
(10), we demonstrated that Th1 cytokines are not over-
expressed in the gut of AS patients without clinical
inflammation, while in CD patients, high levels of all
Th1 cytokines were observed as expected. Although a
trend toward an increase in IFN and TNF mRNA
levels was detected in intestinal biopsy specimens from
AS patients, particularly in those with chronic inflam-
matory lesions, these differences were not significant. In
addition, increased levels of IL-4 and IL-5 mRNA were
detected in mucosal biopsy specimens from some AS
patients. Interestingly, patients with AS (and patients
with CD) displaying high IL-4 or IL-5 levels were
characterized by low IFN expression and vice versa,
possibly suggesting different stages of the inflammatory
response. This evidence strengthens the findings of
previous studies showing that increased expression of
Th2 cytokines characterized different stages of the in-
flammatory lesions in CD patients (40,41). It would be
of interest to investigate whether AS patients displaying
higher levels of IFN are more prone to develop overt
CD.
In summary, this is the first study to demonstrate
that IL-23 is abundantly expressed in the terminal ileum
in AS patients with subclinical gut inflammation at levels
comparable to those found in CD patients. We have also
shown that IL-23 up-regulation is not accompanied by a
defined polarization toward a Th1, Th2, or Th17 pheno-
type, suggesting that the inflammatory lesions in AS
represent an early, possibly preclinical stage of CD.
Finally, we provide evidence that infiltrating cells in
inflammatory lesions in AS and CD and Paneth cells
under pathologic and physiologic conditions are the
main sources of IL-23 in the gut. Overall, these results
strongly support a fundamental role of IL-23/IL-23R
dysregulation as a pathogenetic player and immunologic
marker of subclinical gut inflammation in AS patients.
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